TCBalance Biopharmaceuticals
Pre-clinicalMore than 10% of chronic diseases are due to undesired/pathogenic immune response with high impact for patients and society (>120 bn EUR/a direct health costs alone in EU). Conventional therapy leaves many problems unresolved and usually requires lifelong immunosuppression, which is associated with numerous side effects and high costs, and thus carries a high unmet medical need.
About
More than 10% of chronic diseases are due to undesired/pathogenic immune response with high impact for patients and society (>120 bn EUR/a direct health costs alone in EU). Conventional therapy leaves many problems unresolved and usually requires lifelong immunosuppression, which is associated with numerous side effects and high costs, and thus carries a high unmet medical need.
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile